Items tagged with Prevention
WHO public consultation on draft Target Product Profiles for Tuberculosis Preventive Treatment (post)
01 April 2020 – Tuberculosis (TB) is a major yet preventable global health problem, with an estimated 10 million new cases worldwide in 2018, resulting in more than 1.5 million deaths, making it the leading infectious disease cause of death worldwide. An estimated one-fourth of the world’s population is infected with the TB bacterium, of whom 5–10% advance to active TB disease in their lifetime.
New, shorter treatment to prevent TB to be rolled out in five high-burden TB countries (post)
Three-month regimen expected to prevent TB in those at highest risk of developing the disease, including people living with HIV and children under the age of five.
Brochure for communities: How to Protect Ourselves from TB (post)
The Global Coalition of TB Activists (GCTA) and the World Health Organization Regional Office for South-East Asia released a community friendly brochure on How to Protect Ourselves from TB.
Rifapentine and isoniazid for TB prevention in patients with HIV (post)
Although tuberculosis is relatively uncommon in the United States, it remains a potent killer in less developed regions. In South Africa, TB is the number one cause of death and there is a disproportionate share of HIV-associated tuberculosis. People with HIV are more likely to progress from latent tuberculosis to active tuberculosis disease, making prevention of tuberculosis transmission a priority.
Vitamin D supplementation may not lower risk of TB infection, finds NEJM study (post)
Researchers have found in a new study that vitamin D supplementation did not result in a lower risk of TB infection or TB disease. The study has been published in the New England Journal of Medicine.
Target product profiles for TB preventive treatment (post)
The World Health Organization released target product profiles to drive the rapid development of novel TB preventive treatment. The target product profiles characterise the most important product attributes to be considered for developing the best suited TB prevention treatments in future.
Taking isoniazid preventive therapy during pregnancy not associated with adverse birth outcomes (post)
Pregnant women with HIV who took isoniazid to prevent tuberculosis were more likely to have a live birth and less likely to experience a miscarriage, South African researchers reported this week at the Union World Conference On Lung Health.
The first technology to inactivate COVID-19 virus in fast moving air inactivates the pathogens that cause the common cold, staph infection, influenza, and TB (post)
Dynamics proprietary Nanowave technology, the first technology to inactivate SARS-CoV-2, the virus that causes COVID-19, has successfully inactivated the deadly Staphylococcus bacteria in fast moving air and inactivation rates have been developed for the pathogens that cause the common cold, staph infection, influenza, and tuberculosis, among others. In November, Dynamics released Nanowave Air™, the first publicly available product to incorporate the Nanowave technology.
Cost-effectiveness of scaling up short course preventive therapy for TB among children across 12 countries (post)
A study published in EClinicalMedicine assessed the cost-effectiveness of household contact investigation for TB treatment and short-course preventive therapy provision for children under 15 years old across 12 high TB burden countries.
Virtual symposium: TB Preventive Therapy as Emergency Response to COVID-19 (post)
The Sentinel Project on Pediatric Drug-Resistant Tuberculosis and partners will host a virtual symposium, TB Preventive Therapy as Emergency Response to COVID-19, on 27 January 2021.
Page 7 of 17 · Total posts: 0
←First 6 7 8 Last→